Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 7/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | YES1 | P07947 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | MST1R | Q04912 | 1/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388770 | 1.00 | PELI1 (0.44) | PELI1PYGLKCNA3KDRMET | |
| SCHEMBL8147089 | 0.86 | PELI1 (0.44) | PELI1PYGLKDRMETAURKA | |
| SCHEMBL8147095 | 0.86 | PELI1 (0.44) | PELI1PYGLKDRMETAURKA | |
| SCHEMBL1344144 | 0.84 | KDM4E (0.53) | PYGLKCNA3TDP1 | |
| SCHEMBL13858840 | 0.84 | PYGL (0.45) | PYGLKCNA3GUSBMAOAMAOB | |
| SCHEMBL13858839 | 0.84 | PYGL (0.45) | PYGLKCNA3GUSBMAOAMAOB | |
| SCHEMBL1344147 | 0.84 | KDM4E (0.53) | PYGLKCNA3TDP1 | |
| SCHEMBL8153637 | 0.84 | PTGS2 (0.53) | PELI1KDRPTGS2 | |
| SCHEMBL7621027 | 0.84 | PTGS2 (0.53) | PELI1KDRPTGS2 | |
| SCHEMBL5380483 | 0.84 | PYGL (0.60) | PYGLGUSBPTGS2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247649-B2 | Oxazoles, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| CN-1835947-A | Novel oxazoles, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2006-09-20 | — | — | CN | disclosed |
| EP-1656371-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6984653-B2 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-10 | — | — | US | disclosed |
| WO-2005016921-A2 | NOVEL OXAZOLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | US | disclosed |
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1439178-A1 | HETEROCYCLIC COMPOUNDS, OXAZOLE DERIVATIVES, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242659-A1 | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof | ABL1, JAK1, BTK | PELI1 3084/4885PYGL 1127/4885KCNA3 822/4885 |
| US-20050038091-A1 | Novel oxazoles, their manufacture and use as pharmaceutical agents | OXA1L, CYP11B2, RORB | PELI1 1615/4885PYGL 28/4885KCNA3 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.